A Study of SKB518 in Patients With Lung Cancer
A phase 2 trial of Tislelizumab and Carboplatin in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
A Study of SKB518 in Patients With Lung Cancer is a phase 2 interventional study registered as NCT07019675 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 192 participants planned, started 2025-08-29 and due to reach its primary completion in 2027-02-20. Interventions recorded: SKB518, Tislelizumab and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
Shares Sichuan Kelun-Biotech, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of KL590586 in Patients With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Study of SKB571 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB103 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB565 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB118 Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.